NCT06870838 · ACTIVE NOT RECRUITING
Neuroinflammation in FTLD
This observational study is investigating neuroinflammation in frontotemporal lobar degeneration, a group of brain diseases distinct from Alzheimer's. Researchers are using ultra-high-field 7T MRI scans, spinal fluid, and blood samples to look for biological markers that could distinguish disease subtypes and track progression. No phase is listed because this is not a drug trial — it is a research study collecting data, not testing a treatment.
You may qualify if
- Ability to undergo MRI scanning
- For probable FTLD-tau: a clinical diagnosis of PSP, CBS or nfvPPA, or any clinical FTLD spectrum diagnosis with a proven MAPT mutation
- For probable FTLD-TDP: a clinical diagnosis of svPPA or any clinical FTLD spectrum diagnosis with a proven GRN mutation or C9orf72 repeat expansion
- For presymptomatic mutation carriers: a MAPT mutation, GRN mutation or a C9orf72 mutation without clinical sign of a FTLD spectrum phenotype (CDR 0) For control subjects: no known neurological or psychiatric disorder
- For controls: no known neurological or psychiatric disorder
You're excluded if
- Other neurological or psychiatric disorder that may affect cognitive functions, such as a brain tumour, multiple sclerosis or drug or alcohol abuse or use of psycho-active medications
- CSF profile (β-amyloid, p-tau, t-tau) suggestive of AD pathology
- Clinical dementia Rating Scale (CDR) score >1
- Contra-indication to undergo MRI
- Contra-indication to undergo lumbar puncture
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-11